TwinBeech Capital’s Sage Therapeutics SAGE Stock Holding History

TwinBeech Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-38,114	Closed	-$414K	–	860
2024 Q2	$414K	Sell	38,114 -67,292	-64%	-$862K	0.01%	464
2024 Q1	$1.98M	Buy	105,406 +55,468	+111%	+$1.28M	0.04%	344
2023 Q4	$1.08M	Buy	+49,938	New	+$990K	0.02%	476
2023 Q3	–	Sell	-95,417	Closed	-$4.49M	–	862
2023 Q2	$4.49M	Buy	95,417 +82,316	+628%	+$4.1M	0.09%	255
2023 Q1	$550K	Buy	+13,101	New	+$563K	0.01%	501
2022 Q3	–	Sell	-15,562	Closed	-$503K	–	787
2022 Q2	$503K	Buy	+15,562	New	+$522K	0.02%	417
2021 Q3	–	Sell	-18,317	Closed	-$1.04M	–	733
2021 Q2	$1.04M	Buy	+18,317	New	+$1.29M	0.13%	208
2020 Q1	–	Sell	-7,274	Closed	-$525K	–	440
2019 Q4	$525K	Buy	+7,274	New	+$895K	0.15%	208

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

TwinBeech Capital's SAGE Position: Q3 2024 in Review

TwinBeech Capital sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 38,114 shares — an estimated $414K sold.

TwinBeech Capital first reported a position in SAGE in Q4 2019 and held it in 8 quarters. The position peaked at $4.49M in Q2 2023. 176 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

TwinBeech Capital reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
TwinBeech Capital sold 38,114 Sage Therapeutics shares in Q3 2024, an estimated $414K.
TwinBeech Capital first reported a position in Sage Therapeutics in Q4 2019 and held it in 8 quarters.
TwinBeech Capital's Sage Therapeutics position peaked at $4.49M in Q2 2023.
176 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on TwinBeech Capital's 13F filing for Q3 2024, filed 14 Nov 2024.